Uric acid elevation in atrial fibrillation

Hellenic Journal of Cardiology

Volumn 51, Issue 3, 2010, Pages 209-213

  Letsas, Konstantinos P ^a   Korantzopoulos, Panagiotis ^b   Filippatos, Gerasimos S ^c   Mihas, Constantinos C ^a   Markou, Virginia ^a   Gavrielatos, Gerasimos ^a   Efremidis, Michalis ^a   Sideris, Antonios ^a   Kardaras, Fotios ^a  

^a EVANGELISMOS HOSPITAL   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Atrial fibrillation; C reactive protein; Inflammation; Markers; Oxidative stress; Uric acid; Xanthine oxidase

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; URIC ACID;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; INDEPENDENT VARIABLE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTOR VARIABLE; UNIVARIATE ANALYSIS; URIC ACID BLOOD LEVEL;

AGED; ATRIAL FIBRILLATION; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; URIC ACID;

EID: 77953301536     PISSN: 10117970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am. 2008; 92: 17-40, ix.
2. Vardas PE, Mavrakis HE. Atrial fibrillation: a symptom treated as a disease? Hellenic J Cardiol. 2006; 47: 191-193.
3. Korantzopoulos P, Kolettis T, Siogas K, Goudevenos J. Atrial fibrillation and electrical remodeling: the potential role of inflammation and oxidative stress. Med Sci Monit. 2003; 9: RA225-229.
4. Boos CJ, Anderson RA, Lip GYH. Is atrial fibrillation an inflammatory disorder? Eur Heart J. 2006; 27: 136-149.
5. Ganotakis ES, Mikhailidis DP, Vardas PE. Atrial fibrillation, inflammation and statins. Hellenic J Cardiol. 2006; 47: 51-53.
6. Korantzopoulos P, Kolettis TM, Galaris D, Goudevenos JA. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol. 2007; 115: 135-143. (Pubitemid 46136515)
7. Liu T, Li G, Li L, Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol. 2007; 49: 1642-1648. (Pubitemid 46551628)
8. Lally JA, Gnall EM, Seltzer J, Kowey PR. Non-antiarrhythmic drugs in atrial fibrillation: a review of non-antiarrhythmic agents in prevention of atrial fibrillation. J Cardiovasc Electrophysiol. 2007; 18: 1222-1228. (Pubitemid 47610624)
9. Liu T, Li L, Korantzopoulos P, Liu E, Li G. Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies. Int J Cardiol. 2008; 126: 160-170. (Pubitemid 351602110)
10. Savelieva I, Camm J. Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace. 2008; 10: 647-665. (Pubitemid 351775283)
11. Dawson J, Walters M. Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? Br J Clin Pharmacol. 2006; 62: 633-644.
12. Glantzounis GK, Tsimoyiannis EC, Kappas AM, Galaris DA. Uric acid and oxidative stress. Curr Pharm Des. 2005; 11: 4145-4151.
13. Strazzullo P, Puig JG. Uric acid and oxidative stress: relative impact on cardiovascular risk? Nutr Metab Cardiovasc Dis. 2007; 17: 409-414.
14. Kanellis J, Kang D-H. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol. 2005; 25: 39-42. (Pubitemid 40128147)
15. Corry DB, Tuck ML. Uric acid and the vasculature. Curr Hy- pertens Rep. 2006; 8: 116-119.
16. Lévy S, Camm AJ, Saksena S, et al. International consensus on nomenclature and classification of atrial fibrillation; a collaborative project of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Europace. 2003; 5: 119-122. (Pubitemid 36372367)
17. Nattel S. Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management? Cardiovasc Res. 2002; 54: 347-360.
18. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001; 104: 2886-2891. (Pubitemid 33139098)
19. Neuman RB, Bloom HL, Shukrullah I, et al. Oxidative stress markers are associated with persistent atrial fibrillation. Clin Chem. 2007; 53: 1652-1657. (Pubitemid 47340062)
20. Ruggiero C, Cherubini A, Miller E 3rd, et al. Usefulness of uric acid to predict changes in C-reactive protein and interleukin-6 in 3-year period in Italians aged 21 to 98 years. Am J Cardiol. 2007; 100: 115-121. (Pubitemid 46961911)
21. Dudley SC, Hoch NE, McCann LA, et al. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases. Circulation. 2005; 112: 1266-1273.
22. Thamilarasan M, Grimm RA, Rodriguez LL, et al. Left ventricular diastolic dysfunction in lone atrial fibrillation determined by Doppler tissue imaging of mitral annular motion. Am J Cardiol. 2000; 86: 1026-9, A10.
23. Reant P, Lafitte S, Jaïs P, et al. Reverse remodeling of the left cardiac chambers after catheter ablation after 1 year in a series of patients with isolated atrial fibrillation. Circulation. 2005; 112: 2896-2903. (Pubitemid 41613884)